INNOVATION PHARMACEUTICALS


Associated tags: Pharmaceutical industry, OTCQB, Patient, Medical imaging, Epilepsy, BT, Brain, Neurosurgery, USP, University, News, FDA

Locations: BRAZIL, UNITED STATES, CANDIDA, AUSTRIA, WAKEFIELD, MA, US, ARDS, ISRAEL

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

Retrieved on: 
Monday, August 28, 2023
Epilepsy, Technion – Israel Institute of Technology, Rambam Health Care Campus, Arthroscopy, Elective surgery, Neoplasm, Internet, OTCQB, GE, BT, Brain, Radiology, Gynaecology, Neck, Siemens, Bremen Institute for Applied Beam Technology, MRI, Laser, Neurosurgery, Urology, Patient, Ophthalmology, System, General surgery, Electron-beam additive manufacturing, FDA, Stingray phone tracker, News, Medical imaging

BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations.

Key Points: 
  • BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations.
  • Earlier, BeaMed’s family of laser technologies was cleared by the FDA.
  • BeaMed is on track to submit, in Q2 2024, the System for potential FDA approval via the 510(k) regulatory pathway.
  • We fully expect BeaMed to capitalize on this opportunity as it positions itself for FDA submission by the middle of 2024,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

Retrieved on: 
Wednesday, June 21, 2023
Patent, Biomedical Advanced Research and Development Authority, Gastrointestinal tract, ALI, COVID-19, Infant respiratory distress syndrome, Nature Communications, OTCQB, HDP, Development, Patient, Ulcerative colitis, Biomarker, Acute respiratory distress syndrome, Host, BARDA, Pharmaceutical industry

Brilacidin is a Host Defense Protein-mimetic drug candidate with broad-spectrum immunomodulatory and antimicrobial properties.

Key Points: 
  • Brilacidin is a Host Defense Protein-mimetic drug candidate with broad-spectrum immunomodulatory and antimicrobial properties.
  • The Company out-licensed Brilacidin in UP/UPS to Alfasigma S.p.A. Brilacidin has also been evaluated in Phase 2 testing in moderate-to-severe hospitalized cases of COVID-19 (by intravenous delivery), with beneficial treatment effects observed in patient subgroups.
  • A separate patent application has been submitted to the USPTO for use of Brilacidin in fungal diseases.
  • Additional in vivo testing in efficacy models against two hard-to-treat fungal pathogens is scheduled for 3Q2023.

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

Retrieved on: 
Monday, June 5, 2023
Epilepsy, Seizure, Marketing, OmniGuide, Anatomy, BIRD Foundation, Quality of life, OTCQB, BT, MIT, Medication, Electron-beam technology, MRI, Neurosurgery, Patient, Physician, Algorithm, Engineering, Laser beam machining, Stingray phone tracker, Massachusetts Institute of Technology, Medical imaging, Pharmaceutical industry

An initial area of emphasis of the StingRay System will be for the treatment of epilepsy.

Key Points: 
  • An initial area of emphasis of the StingRay System will be for the treatment of epilepsy.
  • Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment.
  • “Innovation Pharmaceuticals is delighted with the ongoing progress of BeaMed towards creating a groundbreaking product.
  • Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser based medical device spin-off out of the Massachusetts Institute of Technology (MIT).

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

Retrieved on: 
Monday, April 17, 2023
Molecular biology, Canker, University, Genetics, Brazilian Academy of Sciences, Nature Communications, OTCQB, Antifungal, American Academy, Toxicity, Research, USP, European Confederation, Drug resistance, Publication, Caspofungin, Mycology, Fungal infection, Medical Mycology, World Health Organization, Frontiers Media, Pharmaceutical industry, Microbiology

WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of Brilacidin antifungal research in Nature Communications, a leading peer-reviewed scientific journal.

Key Points: 
  • WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of Brilacidin antifungal research in Nature Communications, a leading peer-reviewed scientific journal.
  • The paper, discussing combinations of Brilacidin and other antifungal drugs toward improving treatment outcomes in fungal infections, is available at the link below:
    dos Reis, T.F., de Castro, P.A., Bastos, R.W.
  • A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi .
  • He is an expert in fungal genetics and antifungal resistance and his laboratory at USP focuses on the molecular biology of human fungal pathogens.

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

Retrieved on: 
Wednesday, March 15, 2023
Research, Conference, Histoplasma capsulatum, Mortality, Fungal infection, Pseudallescheria boydii, Voriconazole, São Paulo, Amphotericin B, Immunology, USP, Gordon Research Conferences, Biology, Caspofungin, Fungal keratitis, Micafungin, World Health Organization, Fungus, Fluconazole, Cryptococcosis, OTCQB, Posaconazole, News, University, Pharmaceutical industry, Vaccine, Antibiotics, Mucorales

Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.

Key Points: 
  • Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.
  • USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi.
  • Beyond Brilacidin’s broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.
  • Corresponding posters for these conferences are available on the Events and Presentations section of the Company’s website at the link below.

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

Retrieved on: 
Thursday, February 23, 2023
Marketing, United States patent law, Bremen Institute for Applied Beam Technology, Safety, Ulcer, News, University, Brain, Hospital, Partnership, Software, Risk, BT, GE, USP, FDA, Cone beam computed tomography, Patient, Patent, Ulcerative colitis, Cryptococcus, Inflammatory Bowel Diseases, Gastrointestinal tract, HDP, Patent application, Epilepsy, Preventive healthcare, United States Patent and Trademark Office, Siemens, OTCQB, Medical imaging, Pharmaceutical industry, Aspergillosis

The Company’s Chief Executive Officer and other financial stakeholders in BeaMed recently returned from a visit to Israel to see the StingRay System first-hand.

Key Points: 
  • The Company’s Chief Executive Officer and other financial stakeholders in BeaMed recently returned from a visit to Israel to see the StingRay System first-hand.
  • The StingRay System is a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy, and for improvement of outcomes and minimally invasive surgical options for brain tumors.
  • The first-in-class system is a comprehensive design, with planned robust safety features to constantly monitor thermal energy to minimize risk to healthy tissue.
  • BeaMed aims to offer new hope for this core group of patients, in addition to providing better surgical options for brain tumors.

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement

Retrieved on: 
Monday, January 9, 2023
Brain, OTC, OmniGuide, PACS, FDA, Knowledge, 3D, Partnership, OEM, MIT, Marketing, BIRD Foundation, Beam-powered propulsion, Massachusetts Institute of Technology, Acceleration, Engineering, Temperature, Epilepsy, MRI, Medical imaging

WAKEFIELD, MA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd. (“Shina”), a company specializing in medical imaging software platforms, in order to build on unique capabilities of Shina and accelerate the development, regulatory clearance, and commercial deployment of BeaMed’s StingRay Laser System for brain surgery.

Key Points: 
  • In addition, special software tools will be developed to leverage the unique laser-based surgical tools developed by BeaMed.
  • Shina brings forward decades of relevant experience in rapid development and deployment of medical imaging software suites, including advanced CT/MRI imaging platforms for strategic health companies.
  • “This agreement provides us with two key strategic advantages,” said Gil Shapira, Chief Executive Officer of BeaMed.
  • Shina Systems Ltd. develops and markets clinical image management, PACS and medical imaging analysis application software for almost 3 decades.

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis

Retrieved on: 
Tuesday, December 13, 2022
Eye, Publishing, Posaconazole, Cryptococcus, Mycosis, Voriconazole, Cryptococcosis, Keratitis, Antifungal, Human, Orphan drug, Patient, Toxicity, Mucorales, OTCQB, Research, Mycology, Disease, Fungal keratitis, Caspofungin, University, WHO, Policy, Cornea, World Health Organization, USP, Cryptococcus neoformans, Pharmaceutical industry, Fusarium, Aspergillus

WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.

Key Points: 
  • New in vivo data in an A. fumigatus murine fungal keratitis model showed Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control.
  • Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight.
  • These new Brilacidin findings in fungal keratitis complement an earlier in vitro and in vivo evaluation of Brilacidin as an ocular anti-infective in bacterial keratitis.
  • A broad-spectrum drug that could target both fungal and bacterial keratitis would be uniquely positioned as to its treatment profile and commercial potential.

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

Retrieved on: 
Monday, November 28, 2022
Marketing, Epilepsy, OTC, Anatomy, Neurosurgery, General surgery, Engineering, Food, Brain, BIRD Foundation, Patient, BT, Massachusetts Institute of Technology, Food and Drug Administration, Cardiothoracic surgery, Liver, Prostate, MIT, Stingray phone tracker, Neck, Neoplasm, Oral and maxillofacial surgery, OmniGuide, Lung cancer, Cancer, Prostate cancer, Urology, MANTA, Breast cancer, FDA, Breast, Pharmaceutical industry, Medical imaging, Gynaecology, Orthopedic surgery, Arthroscopy, Radiology, Ophthalmology, Particle beam

WAKEFIELD, MA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BT BeaMedical Technologies (“BeaMed”), a private company developing a next-generation laser-based platform for epilepsy and cancer surgery, has notified Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) that it has received U.S. Food and Drug Administration (FDA) clearance (K222701) for its MANTA surgical laser family. The clearance is an important milestone for BeaMed in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality. Innovation Pharmaceuticals made a strategic investment to acquire a minority stake in BeaMed in June 2022.

Key Points: 
  • WAKEFIELD, MA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BT BeaMedical Technologies (BeaMed), a private company developing a next-generation laser-based platform for epilepsy and cancer surgery, has notified Innovation Pharmaceuticals (OTC: IPIX) (the Company) that it has received U.S. Food and Drug Administration (FDA) clearance (K222701) for its MANTA surgical laser family.
  • Innovation Pharmaceuticals made a strategic investment to acquire a minority stake in BeaMed in June 2022.
  • BeaMed expects to soon make requisite submissions to the FDA for clearance of its fiber optics for use in multiple medical indications.
  • Gil Shapira brings forward 26+ years of engineering and product development and management experience, with over 17 years in the surgical laser industry.

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

Retrieved on: 
Wednesday, October 26, 2022
Innovation, Epilepsy, Company, OTCQB, Disease, Brain, BT, Neurosurgery, Grain, Skull, Laser, Program, NHS, Patient, Technology, Industry, External beam radiotherapy, News, Electron-beam technology, GLOBE, Craniotomy, Seizure, Pain management, United, Pharmaceutical industry, Medical imaging

WAKEFIELD, MA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders insight on a substantial industry development that is relevant to Innovation Pharmaceuticals’ investment in BT BeaMedical Technologies Ltd. (“BeaMed”).

Key Points: 
  • The implications for introducing laser therapy for epilepsy were summed up by the NHS Medical Director for Specialised Services, characterizing the technology as a game-changing breakthrough.
  • Fiber optic laser therapy offers a monumental improvement in epilepsy care.
  • If approved for epilepsy, BeaMed technology likely would increase the number of candidate patients since it is able to target larger areas of the brain.
  • The Company believes that the NHS news further substantiates its investment in BeaMed and the importance of novel laser therapy approaches, which we expect to become the next standard of care for epilepsy.